The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males
- PMID: 38883397
- PMCID: PMC11177789
- DOI: 10.1210/jendso/bvae107
The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males
Abstract
The role of estradiol (E2; an estrogen) in men needs to be more appreciated. In this review, we address the clinical situations that allow the study of the clinical consequences of E2 deficiency in men and discuss the effects of restoration of levels of this reproductive steroid hormone. In men with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT), E2 is suppressed along with testosterone, leading to side effects affecting the quality of life. These include hot flashes, arthralgia, fatigue, mood changes, cognition problems, weight gain, bone loss, and increased risk of cardiovascular disease. Transdermal E2 alone for ADT has shown equivalent testosterone suppression compared to gonadotropin-releasing hormone (GnRH) agonists while also preventing estrogen-deficiency side effects, including hot flashes and bone loss. Co-treatment of ADT with fetal estrogen estetrol (E4) has shown significant improvements of estrogen-deficiency symptoms. These observations emphasize the need to raise awareness of the importance of estrogens in men among clinicians and the lay public.
Keywords: androgen deprivation therapy (ADT); bone loss; estetrol (E4); estrogen deficiency symptoms; hot flashes; transdermal estradiol (tE2).
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.
Figures


Similar articles
-
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review.Endocr Connect. 2022 Nov 18;11(12):e220182. doi: 10.1530/EC-22-0182. Print 2022 Dec 1. Endocr Connect. 2022. PMID: 36283120 Free PMC article. Review.
-
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study.Eur Urol Open Sci. 2022 Oct 3;45:59-67. doi: 10.1016/j.euros.2022.09.006. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36353657 Free PMC article.
-
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.Clin Oncol (R Coll Radiol). 2024 Jan;36(1):e11-e19. doi: 10.1016/j.clon.2023.10.054. Epub 2023 Nov 8. Clin Oncol (R Coll Radiol). 2024. PMID: 37973477 Free PMC article. Clinical Trial.
-
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).Eur Urol Open Sci. 2021 May 6;28:52-61. doi: 10.1016/j.euros.2021.04.005. eCollection 2021 Jun. Eur Urol Open Sci. 2021. PMID: 34337526 Free PMC article.
-
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.Prostate Cancer Prostatic Dis. 2009;12(4):333-8. doi: 10.1038/pcan.2009.35. Epub 2009 Sep 1. Prostate Cancer Prostatic Dis. 2009. PMID: 19901933 Review.
Cited by
-
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1.J Clin Med. 2024 Oct 8;13(19):5996. doi: 10.3390/jcm13195996. J Clin Med. 2024. PMID: 39408055 Free PMC article.
-
Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review).Oncol Lett. 2024 Dec 6;29(2):93. doi: 10.3892/ol.2024.14839. eCollection 2025 Feb. Oncol Lett. 2024. PMID: 39691589 Free PMC article. Review.
References
-
- Parker C, Castro E, Fizazi K, et al. . Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119‐1134. - PubMed
-
- Mohler JL, Antonarakis ES, Armstrong AJ, et al. . Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479‐505. - PubMed
-
- Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(4):333‐338. - PubMed
-
- Pencina KM, Travison TG, Cunningham GR, et al. . Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569‐580. - PubMed
Publication types
LinkOut - more resources
Full Text Sources